{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:13:31Z","timestamp":1788952411615,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Sphingosine-1-phosphate (S1P) receptor modulators are a class of therapeutic agents used for the treatment of multiple sclerosis (MS). There are four S1P modulators currently approved by the Food and Drug Administration\/European Medical Agency (FDA\/EMA): fingolimod, siponimod, ponesimod, and ozanimod. Beyond their well-established immunomodulatory properties, accumulating evidence suggests that these molecules exert direct effects on oligodendrocyte progenitor cells (OPCs) and mature oligodendrocytes, promoting myelin repair through multiple mechanisms.\n                    <jats:italic>In vitro<\/jats:italic>\n                    studies show enhanced OPC differentiation and process extension, while\n                    <jats:italic>in vivo<\/jats:italic>\n                    models demonstrate increased remyelination, improved myelin protein expression, and functional recovery. Imaging studies in people with MS suggest increased myelin repair over time. Potential mechanisms underlying the observed effects involve selective modulation of S1P receptor subtypes (particularly S1PR1, S1PR3, and S1PR5). This comprehensive review summarizes available preclinical and clinical evidence on the role of S1P modulators in remyelination in the context of MS and shows that fingolimod, siponimod and ponesimod possess emerging promise in this field.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1895118","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:31:20Z","timestamp":1788949880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of sphingosine-1-phosphate receptor modulators on remyelination in multiple sclerosis: evidence from in vitro experiments, animal models and human studies"],"prefix":"10.3389","volume":"17","author":[{"given":"Vito A.G.","family":"Ricigliano","sequence":"first","affiliation":[{"name":"Neurology Unit, GHNE Paris-Saclay Hospital","place":["Orsay, France"]},{"name":"Universit\u00e9 Paris-Saclay, UNIACT, Neurospin - INSERM UMR 1129, CEA","place":["Gif-sur-Yvette, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207537","article-title":"Sphingosine-1-phosphate receptor modulators and oligodendroglial cells: Beyond immunomodulation","volume":"21","author":"Roggeri","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/glia.22688","article-title":"Role of p38MAPK in S1P receptor-mediated differentiation of human oligodendrocyte progenitors","volume":"62","author":"Cui","year":"2014","journal-title":"Glia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.24509","article-title":"Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process","volume":"98","author":"Yazdi","year":"2020","journal-title":"J Neurosci Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"I10.011","DOI":"10.1212\/WNL.86.16_supplement.p5.325","article-title":"The sphingosine 1-phosphate (S1P) receptor modulator, siponimod decreases oligodendrocyte cell death and axon demyelination in a mouse model of multiple sclerosis","volume":"86","author":"Tiwari-Woodruff","year":"2016","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202301557RR","article-title":"The sphingosine-1-phosphate receptor 1 modulator ponesimod repairs cuprizone-induced demyelination and induces oligodendrocyte differentiation","volume":"38","author":"Willems","year":"2024","journal-title":"FASEB J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ana.21227","article-title":"FTY720 modulates human oligodendrocyte progenitor process extension and survival","volume":"63","author":"Miron","year":"2008","journal-title":"Ann Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2480","article-title":"Remyelination in the CNS: From biology to therapy","volume":"9","author":"Franklin","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2017.136","article-title":"Regenerating CNS myelin \u2014 from mechanisms to experimental medicines","volume":"18","author":"Franklin","year":"2017","journal-title":"Nat Rev Neurosci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0297-0","article-title":"The direct effects of fingolimod in the central nervous system: Implications for relapsing multiple sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01431-8","article-title":"Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: Differential downstream receptor signalling and clinical profile effects","volume":"81","author":"Chun","year":"2021","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101531R","article-title":"Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P1-selective modulation","volume":"36","author":"Kihara","year":"2022","journal-title":"FASEB J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1516991","article-title":"Sphingosine 1-phosphate receptor 1 modulators exert neuroprotective effects in central nervous system disorders","volume":"16","author":"Chen","year":"2025","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.2174\/0115680266288509240422112839","article-title":"The current landscape in the development of small-molecule modulators targeting sphingosine-1-phosphate receptors to treat neurodegenerative diseases","volume-title":"Ctmc","author":"Kar","year":"2024"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R046300","article-title":"An update on the biology of sphingosine 1-phosphate receptors","volume":"55","author":"Blaho","year":"2014","journal-title":"J Lipid Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrm1103","article-title":"Sphingosine-1-phosphate: An enigmatic signalling lipid","volume":"4","author":"Spiegel","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014154108","article-title":"FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation","volume":"108","author":"Choi","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4645-04.2005","article-title":"Edg8\/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival","volume":"25","author":"Jaillard","year":"2005","journal-title":"J Neurosci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2009.04.002","article-title":"Sphingosine-1-phosphate and oligodendrocytes: From cell development to the treatment of multiple sclerosis","volume":"91","author":"Coelho","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15050436","article-title":"Sphingosine-1-phosphate modulation in neurological disorders: Insights from MS and stroke","volume":"15","author":"Maktabi","year":"2025","journal-title":"Brain Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.080478","article-title":"Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod","volume":"173","author":"Miron","year":"2008","journal-title":"Am J Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.80.7_supplement.P05.150","article-title":"Effects of S1P receptor modulator FTY720 on human oligodendrocyte progenitor cell differentiation","volume":"80","author":"Cui","year":"2013","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuroscience.2015.10.013","article-title":"Enhanced remyelination following lysolecithin-induced demyelination in mice under treatment with fingolimod (FTY720)","volume":"311","author":"Yazdi","year":"2015","journal-title":"Neuroscience"},{"key":"B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.nbd.2015.01.006","article-title":"Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis","volume":"76","author":"Cui","year":"2015","journal-title":"Neurobiol Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.091234","article-title":"Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices","volume":"176","author":"Miron","year":"2010","journal-title":"Am J Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00014","article-title":"Combination therapy with fingolimod and neural stem cells promotes functional myelination in vivo through a non-immunomodulatory mechanism","volume":"13","author":"Zhang","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577091","article-title":"Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model","volume":"339","author":"Nystad","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673435364251002112630","article-title":"Neuroinflammatory human brain organoids enable comprehensive drug screening studies: Fingolimod and its analogues in focus","volume":"33","author":"Acar","year":"2025","journal-title":"Curr Med Chem"},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12883-020-01645-z","article-title":"Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) \u2013 preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial","volume":"20","author":"Albert","year":"2020","journal-title":"BMC Neurol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.01.009","article-title":"q-Space myelin map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with fingolimod: A preliminary study","volume":"373","author":"Tanikawa","year":"2017","journal-title":"J Neurol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00997-1","article-title":"Effects of fingolimod and natalizumab on brain T1-\/T2-weighted and magnetization transfer ratios: A 2-year study","volume":"18","author":"Preziosa","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001161","article-title":"Increased remyelination and proregenerative microglia under siponimod therapy in mechanistic models","volume":"9","author":"Dietrich","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12974-016-0494-x","article-title":"The dual S1PR1\/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures","volume":"13","author":"O\u2019Sullivan","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-76","article-title":"Fingolimod modulates microglial activation to augment markers of remyelination","volume":"8","author":"Jackson","year":"2011","journal-title":"J Neuroinflamm"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517721355","article-title":"The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination","volume":"24","author":"Mannioui","year":"2018","journal-title":"Mult Scler J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1038\/s41598-025-87825-8","article-title":"Siponimod supports remyelination in the non-supportive environment","volume":"15","author":"Kr\u00fcger","year":"2025","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2022.1068736","article-title":"Therapeutic effect of combination vitamin D3 and siponimod on remyelination and modulate microglia activation in cuprizone mouse model of multiple sclerosis","volume":"16","author":"Al-Otaibi","year":"2023","journal-title":"Front Behav Neurosci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12974-016-0686-4","article-title":"Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis","volume":"13","author":"Gentile","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221076717","article-title":"Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial","volume":"28","author":"Arnold","year":"2022","journal-title":"Mult Scler J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","article-title":"An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis","volume":"24","author":"Dumitrescu","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"B42","article-title":"Preservation of myelin in patients with relapsing multiple sclerosis treated with ponesimod compared to teriflunomide","author":"Datta","year":""},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01116-w","article-title":"Ozanimod: A review in relapsing forms of multiple sclerosis","volume":"38","author":"Nie","year":"2024","journal-title":"CNS Drugs"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.121.000741","article-title":"Deconstructing the pharmacological contribution of sphingosine-1 phosphate receptors to mouse models of multiple sclerosis using the species selectivity of ozanimod, a dual modulator of human sphingosine 1-phosphate receptor subtypes 1 and 5","volume":"379","author":"Selkirk","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020357","article-title":"Identifying biomarkers for remyelination and recovery in multiple sclerosis: A measure of progress","volume":"13","author":"Ricigliano","year":"2025","journal-title":"Biomedicines"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02094-5","article-title":"Targeting the sphingosine-1-phosphate pathway: New opportunities in inflammatory bowel disease management","volume":"84","author":"Kitsou","year":"2024","journal-title":"Drugs"},{"key":"B47","article-title":"Title: Restoring the multiple sclerosis associated imbalance of gut indole metabolites promotes remyelination and suppresses neuroinflammation","author":"Jank","year":"2025"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1895118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:31:22Z","timestamp":1788949882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1895118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2026.1895118"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1895118","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1895118"}}